“…Long non-coding RNAs (lncRNAs) with a sequence of longer than 200 nt play vital regulatory functions in diverse cellular and physiological processes, including cell differentiation, chromatin remodeling, post-transcriptional regulation, and epigenetic control of gene expression. , Abnormal expression of lncRNAs is linked to various diseases, such as type-2 diabetes mellitus, cardiomyopathy, and cancers (e.g., hepatocellular carcinoma, breast, cervical, and prostate cancers). − In particular, lncRNAs act as key regulators involved in various biological processes of cancers, including tumor formation, progression, proliferation, invasion, metastasis, and drug resistance . For example, the lncRNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) sequesters miRNAs by miRNA response elements (MREs) located in the MALAT1 sequence, alleviating the suppressive effect of tumor suppressor miRNAs (TSmiRs) on oncogenic targets to promote proliferation and invasion of tumor cells. , Moreover, lncRNAs exhibit good resistance to RNase digestion and circulate in body fluids with higher stability (e.g., half-life time of 9–12 h for MALAT1). , LncRNAs have been recognized as both non-invasive cancerous biomarkers and promising therapeutic targets. , Accordingly, sensitive detection of lncRNA is of vital importance for early clinical diagnosis, lncRNA-targeted treatment, and prognosis monitoring of tumors.…”